Michelle F. Waldman

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> ^CRBN </scp>

Anita K. Gandhi, Jian Kang, Courtney G. Havens et al. · British Journal of Haematology · 2013 · 621 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Patrick R. Hagner, Hon‐Wah Man, Celia Fontanillo et al. · Blood · 2015 · 200 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Anita K. Gandhi, Derek Mendy, Michelle F. Waldman et al. · British Journal of Haematology · 2013 · 104 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of a Novel Class of Orally Active Antifungal β-1,3- <scp>d</scp> -Glucan Synthase Inhibitors

Scott S. Walker, Yiming Xu, Ilias Triantafyllou et al. · Antimicrobial Agents and Chemotherapy · 2011 · 75 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

Nicholas J. Vogelzang, Karim Fizazi, John M. Burke et al. · European Urology · 2016 · 64 citations

Medicine, Oncology, Pharmacology +16